Cassava Sciences Inc vs Petróleo Brasileiro SA — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Petróleo Brasileiro SA trades at $24.51 (market cap $149.03B). The key difference: Petróleo Brasileiro SA is far larger — about 3782.5× Cassava Sciences Inc's market cap, and Petróleo Brasileiro SA pays a 6.98% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Petróleo Brasileiro SA for 25 Days on average.
| FLNA | PBR | |
|---|---|---|
Market Cap | $39.40M | $149.03B |
Volume | 759,018 | 30,322,411 |
Sector | Health | Energy |
52-Week High | $4.64 | $24.69 |
52-Week Low | $0.68 | $11.54 |
Typical Hold Time | 37 Days | 25 Days |
Enterprise Value | -$43.28M | $209.45B |
Dividend Yield | — | 6.98% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Petrobras (PBR) trades at $23.99, up 0.8% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.06, net income margin of 24.52%, and ROE of 30.77%. Recent Q2 2026 earnings beat expectations at $1.62 EPS versus $1.52 expected. Positive developments include new oil discoveries and platform deployments boosting production capacity.
PBR presents compelling value with attractive valuation metrics and strong profitability, though current price sits near analyst consensus target of $22.33. Key risks include political interference in Brazil and capital expenditure pressures. The stock offers dividend yield potential with recent $0.53 dividend declaration, supported by 50% analyst buy ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →